Xencor, Inc. Profile Avatar - Palmy Investing

Xencor, Inc.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that tar…

Biotechnology
US, Monrovia [HQ]

Risk Factors

By Management
10-K
  1. We rely on third parties to manufacture supplies of our preclinical and clinical product candidates. The development of such candidates could be stopped or delayed if any such third party fails to provide us with sufficient quantities of product or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance.

  2. We rely on third-party manufacturers to manufacture our product candidates and provide supplies for our studies. If any of our third-party manufacturers, encounter problems or loss of drug material during production or otherwise fail to comply with their contractual obligations, the development of our product candidates could be delayed or stopped.

  3. Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.

Get PRO Today.

Read 22 more risk factors of Xencor, Inc.

End of XNCR's Analysis
CIK: 1326732 CUSIP: 98401F105 ISIN: US98401F1057 LEI: - UEI: -
Secondary Listings
XNCR has no secondary listings inside our databases.